Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the research, development, and commercialization of medicines for infectious diseases, with an emphasis on conditions prevalent in tropical and subtropical regions. The company operates within the biopharmaceutical and infectious disease industries and is publicly traded on the Nasdaq Capital Market under the ticker SXTP. Its business model centers on acquiring, developing, and commercializing late-stage or approved therapies that address unmet medical needs.
The company’s primary revenue driver is ARAKODA®, an FDA-approved oral antimalarial drug for the prophylaxis of malaria, licensed from GlaxoSmithKline plc. 60 Degrees Pharmaceuticals positions itself as a niche player targeting diseases that are often underrepresented by large pharmaceutical companies, particularly those affecting travelers, military personnel, and populations in endemic regions. The company was founded in 2010 and has evolved from a development-stage entity into a commercial-stage pharmaceutical company following the U.S. approval and launch of ARAKODA® in 2018.
Business Operations
Business operations are primarily organized around a single operating segment focused on infectious disease therapeutics, with commercial and development activities closely integrated. Revenue is generated predominantly through U.S. sales of ARAKODA®, distributed to government agencies, including the U.S. Department of Defense, as well as to civilian travel medicine markets. International revenue has historically been limited, with commercial efforts concentrated in the United States.
The company controls commercial rights to ARAKODA® in the U.S. and certain other territories through licensing agreements, while continuing clinical development of tafenoquine for additional indications. 60 Degrees Pharmaceuticals operates without large-scale manufacturing assets, relying instead on third-party manufacturers and contract research organizations. Its principal operating subsidiary is 60 Degrees Pharmaceuticals, LLC, which holds rights to its commercial and development-stage assets.
Strategic Position & Investments
Strategically, 60 Degrees Pharmaceuticals aims to expand the clinical and commercial value of tafenoquine by pursuing additional indications beyond malaria prophylaxis, most notably babesiosis, a tick-borne infectious disease. Clinical development programs have focused on evaluating tafenoquine as a potential treatment option in areas where current standards of care are limited or burdensome.
The company’s growth strategy relies more on targeted clinical development and label expansion than on large-scale acquisitions. While it has evaluated opportunities to in-license or acquire complementary infectious disease assets, publicly available disclosures indicate that its primary investment focus remains the advancement of its existing pipeline rather than building a diversified portfolio. Data on additional acquisitions or equity investments beyond its core programs is inconclusive based on available public sources.
Geographic Footprint
60 Degrees Pharmaceuticals is headquartered in Washington, D.C., and its operational footprint is primarily concentrated in North America. The company’s commercial activities are focused on the United States, where ARAKODA® is approved and marketed. International exposure is largely indirect, tied to global malaria prevention needs and government-related procurement rather than broad-based commercial infrastructure abroad.
While the company engages with international health stakeholders and global regulatory considerations through clinical development and licensing arrangements, it does not maintain a significant physical presence or standalone commercial operations across Europe, Africa, or Asia-Pacific. Its geographic influence is therefore driven more by product applicability than by operational scale.
Leadership & Governance
60 Degrees Pharmaceuticals is led by an executive team with experience in pharmaceuticals, commercialization, and infectious disease development. The leadership emphasizes capital discipline, targeted clinical investment, and addressing unmet needs in niche markets rather than pursuing broad therapeutic expansion. Governance follows standard public company practices, with oversight by a board of directors.
Key executives include:
- Geoff Dow – Chief Executive Officer
- David F. Feely – Chief Financial Officer
- Kevin C. Neel – Chief Operating Officer
Information regarding founders and additional executive leadership roles beyond those listed above is limited in publicly available filings, and data is inconclusive based on available public sources.